A Clinician's Pearls & Myths in Rheumatology
Editat de John H. Stoneen Limba Engleză Paperback – apr 2024
This book builds upon the first edition with new and improved chapters. The book explores the rich assemblage of clinical wisdom from expert rheumatologists from a wide range of specialties including Vasculitis and Sjogren’s syndrome. It examines the nuggets or ‘pearls’ of wisdom gained from collective clinical experience about the diagnosis or treatment of various diseases whilst also aiming to debunk myths that have influenced the practice of rheumatology by many clinicians.
The second edition of A Clinician's Pearls and Myths in Rheumatology is a critical resource for both practitioners and students of rheumatology. This book provides a clear guide for those wishing to take a “deep dive” into the diagnostic and therapeutic elements of rheumatology.
The second edition of A Clinician's Pearls and Myths in Rheumatology is a critical resource for both practitioners and students of rheumatology. This book provides a clear guide for those wishing to take a “deep dive” into the diagnostic and therapeutic elements of rheumatology.
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (2) | 583.04 lei 39-44 zile | |
| SPRINGER LONDON – 23 aug 2016 | 583.04 lei 39-44 zile | |
| Springer International Publishing – apr 2024 | 653.42 lei 39-44 zile | |
| Hardback (1) | 841.72 lei 3-5 săpt. | +102.45 lei 6-12 zile |
| Springer International Publishing – 31 mar 2023 | 841.72 lei 3-5 săpt. | +102.45 lei 6-12 zile |
Preț: 653.42 lei
Preț vechi: 687.80 lei
-5% Nou
Puncte Express: 980
Preț estimativ în valută:
125.09€ • 130.03$ • 103.71£
125.09€ • 130.03$ • 103.71£
Carte tipărită la comandă
Livrare economică 03-08 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783031234903
ISBN-10: 3031234901
Pagini: 771
Ilustrații: XXIII, 771 p. 426 illus., 320 illus. in color.
Dimensiuni: 210 x 279 mm
Ediția:2nd ed. 2023
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3031234901
Pagini: 771
Ilustrații: XXIII, 771 p. 426 illus., 320 illus. in color.
Dimensiuni: 210 x 279 mm
Ediția:2nd ed. 2023
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
V-ar putea interesa
-
Primer on the Rheumatic DiseasesJohn H. Klippel-5%Preț: 877.67 lei923.86 lei -
-5%Preț: 1050.68 lei1105.99 lei -
Review of RheumatologyNona T. Colburn-5%Preț: 787.05 lei828.47 lei -
Rheumatology in PracticeJ.A. Pereira da Silva-5%Preț: 795.67 lei837.54 lei -
Sjögren’s Syndrome: Diagnosis and TherapeuticsManuel Ramos-Casals-5%Preț: 804.20 lei846.52 lei -
Ankylosing spondylitis and KlebsiellaAlan Ebringer-5%Preț: 1088.96 lei1146.26 lei -
Behçet’s SyndromeYusuf Yazıcı-5%Preț: 1269.65 lei1336.47 lei -
Challenging Cases in Rheumatology and Diseases of the Immune SystemMassoud Mahmoudi-5%Preț: 1314.08 lei1383.24 lei -
The Inflammatory MyopathiesLawrence J. Kagen-5%Preț: 1013.51 lei1066.85 lei -
Atlas of Postmenopausal Osteoporosis: Third EditionRene Rizzoli-5%Preț: 358.12 lei376.97 lei -
Diverticular DiseaseP Black-5%Preț: 349.51 lei367.91 lei -
Performing Arts Medicine in Clinical PracticeHoward A. Bird-5%Preț: 695.89 lei732.51 lei -
Familial Mediterranean FeverMarco Gattorno-5%Preț: 763.05 lei803.21 lei -
Vasculitis in Clinical PracticeRichard A. Watts-5%Preț: 862.04 lei907.41 lei -
-5%Preț: 690.75 lei727.10 lei -
Hughes Syndrome: A Patient’s GuideGraham Hughes-5%Preț: 498.61 lei524.85 lei -
Dictionary of RheumatologyJozef Rovenský-5%Preț: 1075.86 lei1132.49 lei -
-5%Preț: 572.27 lei602.40 lei -
-5%Preț: 456.55 lei480.57 lei -
Der Schmerz- und RheumakrankeRudolf Klußmann-5%Preț: 458.92 lei483.07 lei -
-5%Preț: 702.71 lei739.69 lei -
-5%Preț: 467.09 lei491.67 lei -
-5%Preț: 731.17 lei769.65 lei -
Rheumatoid Arthritis: Recent Research AdvancesJosef S. Smolen-5%Preț: 1078.90 lei1135.68 lei -
IgG4-Related DiseaseHisanori Umehara-5%Preț: 904.55 lei952.16 lei -
IgG4-Related Kidney DiseaseTakao Saito-5%Preț: 1097.47 lei1155.23 lei
Cuprins
Rheumatoid Arthritis.- Rheumatoid Vasculitis.- Adult-Onset Still's Disease.- Juvenile Idiopathic Arthritis.- Monogenic Autoinflammatory Syndromes.- Juvenile Spondyloarthropathy.- Ankylosing Spondylitis.- Psoriatic Arthritis.- Reactive Arthritis.- Systemic Sclerosis (Scleroderma) and Raynaud’s Phenomenon.- Nephrogenic Systemic Fibrosis and Other Scleroderma Mimickers.- Sjögren's Syndrome.- Systemic Lupus Erythematosus.- Pediatric Systemic Lupus Erythematosus.- Mixed Connective Tissue Disease.- The Antiphospholipid Syndrome.- Pregnancy in the Rheumatic Diseases.- Inflammatory Myopathies.- Juvenile Dermatomyositis.- Vasculitic Neuropathy.- Pediatric Vasculitis.- Behçet's Syndrome.- The Churg—Strauss Syndrome.- ANCA-Associated Vasculitis.- Cryoglobulinemia.- Polyarteritis Nodosa.- Giant Cell Arteritis and Polymyalgia Rheumatica.- Takayasu's Arteritis.- Primary Angiitis of the Central Nervous System and Reversible Cerebral Vasoconstriction Syndromes.- Thromboangiitis Obliterans (Buerger's Disease).- Less Common Forms of Vasculitis.- Relapsing Polychondritis.- Fibromyalgia.- The Clinical Features of Gout.- Gout Epidemiology.- Gout Treatment.- Calcium Pyrophosphate Dihydrate (CPPD) Crystal Deposition Disease.- Inflammatory Eye Disease.- Immune-Mediated Inner Ear Disease.- Osteoporosis.- Paget's Disease of Bone.- Sarcoidosis.- Osteoarthritis.- Regional Musculoskeletal Complaints.- Low Back and Neck Pain.- Amyloidosis.- The Ehlers—Danlos Syndrome.- Osteonecrosis.
Notă biografică
John H. Stone MD, MPH. Professor of Medicine, Harvard Medical School. The Edward A. Fox Chair in Medicine, Massachusetts General Hospital, Boston, MA, USA.
He writes: I have had a career-long interest in teaching, research, and clinical care of patients with rheumatic diseases; i.e., inflammatory diseases mediated by patients’ overly active immune systems. My work has focused on the systemic vasculitides, particularly ANCA-associated vasculitis and giant cell arteritis; IgG4-related disease (IgG4-RD); and glucocorticoid toxicity. Following medical school at Harvard Medical School, internal medicine training at Johns Hopkins, and a rheumatology fellowship at the University of California-San Francisco, I co-founded and directed the Vasculitis Center at Johns Hopkins University. This Center was the first in the United States to focus on inflammatory diseases of blood vessels such as ANCA-associated vasculitis and giant cell arteritis.
At JohnsHopkins, I directed the first NIH-funded, multi-center clinical trial in granulomatosis with polyangiitis. The results of this trial were published in The New England Journal of Medicine (2005). This trial paved the way for subsequent trials and investigations in vasculitis on an international scale. Work at the Johns Hopkins Vasculitis Center blazed a path for physicians all over the world interested in vasculitis, encouraging them to focus on research in this area. This effort ultimately served as the impetus for dozens of clinical trials in these diseases that have led to substantially better treatments for patients in less than 20 years.
In 2008, I was recruited to become the Director of Clinical Rheumatology at the Massachusetts General Hospital (MGH), where I have continued my interest in vasculitis from the research standpoint and broadened my clinical scope to include the full breadth of rheumatology. I was the Co-Principal Investigator on the Rituximab in ANCA-associated Vasculitis (RAVE) trial, funded by the Immune Tolerance Network at the NIH. This trial led to two New England Journal of Medicine papers and changed the standard of care for remission induction in this disease. RAVE formed the basis of approval of rituximab (Rituxan) by the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA) for remission induction in ANCA-associated vasculitis. I have also been the global Principal Investigator of a multi-center clinical trial of interleukin-6 receptor (IL6R) blockade in giant cell arteritis. Giant cell arteritis is a disease that currently affects 300,000 Americans, and aside from prednisone there had been no other effective therapy known for nearly seventy years. The trial, known as GiACTA. This trial, conducted at 76 sites across North America and Europe, ledto a “breakthrough designation” for tocilizumab by the FDA for giant cell arteritis and approval by the agency in 2017. The drug has also been approved in Europe for giant cell arteritis, and in Japan it is approved for Takayasu’s arteritis, a related form of vasculitis, as well – all on the strength of this one trial. The primary results of this trial were published in The New England Journal of Medicine (2017). The trial demonstrated for the first time ever the availability of an effective steroid-sparing approach to the treatment of giant cell arteritis.
My second major research interest pertains to an emerging disease, IgG4-RD. My group at the MGH has identified several new disease associations with IgG4-RD, including lymphoplasmacytic thoracic aortitis, eosinophilic angiocentric fibrosis, Riedel’s thyroiditis, and midline destructive disease. My group also made the novel observation that B cell depletion with rituximab leads to swift, targeted declines in serumIgG4 concentrations (the other IgG subclasses remain stable), associated with dramatic clinical improvement. I was the first author on an NEJM Mechanisms of Disease paper in 2012 entitled “IgG4-Related Disease” and the senior author on a Lancet review (2014). I was the Principal Investigator on an NIH-funded R13 grant to conduct the world’s first International Symposium on IgG4-RD (2011). Three subsequent international symposia on IgG4-RD have followed, and a fifth is planned.
Finally, a burgeoning research interest in the last couple of years pertains to the measurement and prevention of steroid toxicity. Steroids remain the cornerstone of treating many immune-mediated diseases, but their toxicities are well-known and generally reviled by physicians and patients alike. I organized an international group of sub-specialty experts to create a Glucocorticoid Toxicity Index (GTI), designed for use as an outcome measurein clinical trials. We have created a version of this instrument designed for use in adult patients that has now been licensed for use in clinical trials across twenty disease indications. A pediatric version of the instrument has also been developed, and both instruments are available on digital platforms.
One of the career achievements of which I am most proud, however, is A Clinician’s Pearls & Myths in Rheumatology, now in its second edition. This book involves a collaboration of more than 200 international experts who share their insights about this remarkable specialty of ours.
Over the span of my career, I have had the privilege of witnessing and in some cases helping in the transition of treatment for patients with inflammatory diseases – rheumatoid arthritis, lupus, vasculitis, IgG4-RD, and many more – out of the Dark Ages of limited therapeutic options with toxic side-effects, into an era of safe, highly effective medications. We have made great progress thus far, and I anticipate an acceleration of the pace between now and the third edition of A Clinician’s Pearls & Myths.
He writes: I have had a career-long interest in teaching, research, and clinical care of patients with rheumatic diseases; i.e., inflammatory diseases mediated by patients’ overly active immune systems. My work has focused on the systemic vasculitides, particularly ANCA-associated vasculitis and giant cell arteritis; IgG4-related disease (IgG4-RD); and glucocorticoid toxicity. Following medical school at Harvard Medical School, internal medicine training at Johns Hopkins, and a rheumatology fellowship at the University of California-San Francisco, I co-founded and directed the Vasculitis Center at Johns Hopkins University. This Center was the first in the United States to focus on inflammatory diseases of blood vessels such as ANCA-associated vasculitis and giant cell arteritis.
At JohnsHopkins, I directed the first NIH-funded, multi-center clinical trial in granulomatosis with polyangiitis. The results of this trial were published in The New England Journal of Medicine (2005). This trial paved the way for subsequent trials and investigations in vasculitis on an international scale. Work at the Johns Hopkins Vasculitis Center blazed a path for physicians all over the world interested in vasculitis, encouraging them to focus on research in this area. This effort ultimately served as the impetus for dozens of clinical trials in these diseases that have led to substantially better treatments for patients in less than 20 years.
In 2008, I was recruited to become the Director of Clinical Rheumatology at the Massachusetts General Hospital (MGH), where I have continued my interest in vasculitis from the research standpoint and broadened my clinical scope to include the full breadth of rheumatology. I was the Co-Principal Investigator on the Rituximab in ANCA-associated Vasculitis (RAVE) trial, funded by the Immune Tolerance Network at the NIH. This trial led to two New England Journal of Medicine papers and changed the standard of care for remission induction in this disease. RAVE formed the basis of approval of rituximab (Rituxan) by the U.S. Food & Drug Administration (FDA), the European Medicines Agency (EMA) for remission induction in ANCA-associated vasculitis. I have also been the global Principal Investigator of a multi-center clinical trial of interleukin-6 receptor (IL6R) blockade in giant cell arteritis. Giant cell arteritis is a disease that currently affects 300,000 Americans, and aside from prednisone there had been no other effective therapy known for nearly seventy years. The trial, known as GiACTA. This trial, conducted at 76 sites across North America and Europe, ledto a “breakthrough designation” for tocilizumab by the FDA for giant cell arteritis and approval by the agency in 2017. The drug has also been approved in Europe for giant cell arteritis, and in Japan it is approved for Takayasu’s arteritis, a related form of vasculitis, as well – all on the strength of this one trial. The primary results of this trial were published in The New England Journal of Medicine (2017). The trial demonstrated for the first time ever the availability of an effective steroid-sparing approach to the treatment of giant cell arteritis.
My second major research interest pertains to an emerging disease, IgG4-RD. My group at the MGH has identified several new disease associations with IgG4-RD, including lymphoplasmacytic thoracic aortitis, eosinophilic angiocentric fibrosis, Riedel’s thyroiditis, and midline destructive disease. My group also made the novel observation that B cell depletion with rituximab leads to swift, targeted declines in serumIgG4 concentrations (the other IgG subclasses remain stable), associated with dramatic clinical improvement. I was the first author on an NEJM Mechanisms of Disease paper in 2012 entitled “IgG4-Related Disease” and the senior author on a Lancet review (2014). I was the Principal Investigator on an NIH-funded R13 grant to conduct the world’s first International Symposium on IgG4-RD (2011). Three subsequent international symposia on IgG4-RD have followed, and a fifth is planned.
Finally, a burgeoning research interest in the last couple of years pertains to the measurement and prevention of steroid toxicity. Steroids remain the cornerstone of treating many immune-mediated diseases, but their toxicities are well-known and generally reviled by physicians and patients alike. I organized an international group of sub-specialty experts to create a Glucocorticoid Toxicity Index (GTI), designed for use as an outcome measurein clinical trials. We have created a version of this instrument designed for use in adult patients that has now been licensed for use in clinical trials across twenty disease indications. A pediatric version of the instrument has also been developed, and both instruments are available on digital platforms.
One of the career achievements of which I am most proud, however, is A Clinician’s Pearls & Myths in Rheumatology, now in its second edition. This book involves a collaboration of more than 200 international experts who share their insights about this remarkable specialty of ours.
Over the span of my career, I have had the privilege of witnessing and in some cases helping in the transition of treatment for patients with inflammatory diseases – rheumatoid arthritis, lupus, vasculitis, IgG4-RD, and many more – out of the Dark Ages of limited therapeutic options with toxic side-effects, into an era of safe, highly effective medications. We have made great progress thus far, and I anticipate an acceleration of the pace between now and the third edition of A Clinician’s Pearls & Myths.
Textul de pe ultima copertă
This book builds upon the first edition with new and improved chapters. The book explores the rich assemblage of clinical wisdom from expert rheumatologists from a wide range of specialties including Vasculitis and Sjogren’s syndrome. It examines the nuggets or ‘pearls’ of wisdom gained from collective clinical experience about the diagnosis or treatment of various diseases whilst also aiming to debunk myths that have influenced the practice of rheumatology by many clinicians.
The second edition of A Clinician's Pearls and Myths in Rheumatology is a critical resource for both practitioners and students of rheumatology. This book provides a clear guide for those wishing to take a “deep dive” into the diagnostic and therapeutic elements of rheumatology.
The second edition of A Clinician's Pearls and Myths in Rheumatology is a critical resource for both practitioners and students of rheumatology. This book provides a clear guide for those wishing to take a “deep dive” into the diagnostic and therapeutic elements of rheumatology.
Caracteristici
Debunks false myths that have influenced clinical practice Examines the nuggets of wisdom, pearls gained from collective clinical experience
Recenzii
From the reviews:
“This is a complete review of basic rheumatology presented in an easy-to-read format. … It appears to be written for medical students, residents, rheumatology fellows, and general practitioners in family and internal medicine. … Numerous high-quality color photographs aid in the visualization of many of the described clinical manifestations. The unique presentation, using pearls and myths, lends an easy-to-read style to the book.” (Kristi Kuhn, Doody’s Review Service, March, 2010)
“This book is fun to read and use. … It offers valuable insights applicable to daily practice and enhances many teaching points with evidence-based support, both pro and con. … I give this text my highest recommendation to all those practicing and teaching rheumatology. A Clinician's Pearls and Myths in Rheumatology is satisfying to read and seems to offer more practical information for the clinician practicing rheumatology than most of the online or print textbooks that I regularly refer to.” (Robert J. Quinet, Journal of the American Medical Association, Vol. 304 (6), August, 2010)
“This is a complete review of basic rheumatology presented in an easy-to-read format. … It appears to be written for medical students, residents, rheumatology fellows, and general practitioners in family and internal medicine. … Numerous high-quality color photographs aid in the visualization of many of the described clinical manifestations. The unique presentation, using pearls and myths, lends an easy-to-read style to the book.” (Kristi Kuhn, Doody’s Review Service, March, 2010)
“This book is fun to read and use. … It offers valuable insights applicable to daily practice and enhances many teaching points with evidence-based support, both pro and con. … I give this text my highest recommendation to all those practicing and teaching rheumatology. A Clinician's Pearls and Myths in Rheumatology is satisfying to read and seems to offer more practical information for the clinician practicing rheumatology than most of the online or print textbooks that I regularly refer to.” (Robert J. Quinet, Journal of the American Medical Association, Vol. 304 (6), August, 2010)